Lee, Han Chu

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 1,120

Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification

Ahn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Genomics and Diagnostics

Cited by 424

MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma

Kim, S. Y., An, J., Lim, Y.-S., Han, S., Lee, J.-Y., Byun, J. H., Won, H. J., Lee, S. J., Lee, H. C., & Lee, Y. S. (2017) · JAMA Oncology

Hepatocellular Carcinoma Treatment and PrognosisMRI in cancer diagnosis

Cited by 356

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 326

Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment

Yoo, S., Lee, D., Shim, J. H., Kim, K. M., Lim, Y.-S., Lee, H. C., Yoo, C., Ryoo, B.-Y., & Choi, J. (2022) · Clinical Gastroenterology and Hepatology

Hepatitis B Virus StudiesHepatitis C virus research

Cited by 73